附註:Includes bibliographical references and index.
Preface -- Chapter 1. History and Epidemiology of Parkinson's Disease -- Chapter 1. Epidemiology of Parkinson's Disease: An Updated Overview -- Chapter 2. Sympatomatology and Diagnosis of Parkinson's Disease -- Chapter 2. Symptomatology and Clinical Features of Parkinson's Disease -- Chapter 3. Non-Motor Symptoms in Parkinson's Disease: The Other Side of the Disease -- Chapter 4. Diagnosing Methods of Parkinson's Disease: Revolutionary Techniques -- Chapter 5. Diagnostic Biomarkers of Parkinson's Disease -- Chapter 3. Neuropathology of Parkinson's Disease -- Chapter 6. Neuropathology of Parkinson's Disease: An Update of the Recent Findings -- Chapter 7. Clinical and Experimental Evidence of Cirrhosis-Related Parkinsonism -- Chapter 4. Etiologies and Risk Factors of Parkinson's Disease -- Chapter 8. Parkinson's Disease: Clinical Manifestations and Risk Factors -- Chapter 9. Sex Dimorphism and Parkinson's Disease: What We Learned -- Chapter10. An Overview of the Genetics of Parkinson's Disease -- Chapter 11. Pesticide Exposure as a Risk Factor for Parkinson's Disease -- Chapter 12. Impact of Hydrocarbon Exposure on the Risk of Parkinson's Disease -- Chapter 5. Management of Parkinson's Disease: Pharmacological and Non-Pharmacological Treatments -- Chapter 13. Pharmacological Treatments of Parkinson's Disease: Preventing and Curing Approaches -- Chapter 14. Parkinson's Disease Related to Food and Nutrition: WhatWe Learned -- Chapter 15. Chitosan and Its Derivatives as Potential Neuro-Protective Agents for the Treatment of Parkinson's Disease -- Chapter 16. Effects of Physical Activity on Pakinson's Disease Patients -- Chapter 17. Potential Role of Probiotics and Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease -- Chapter 18. Stem Cells: The New Hope for Parkinson's Disease Treatment -- Compilation of References -- About the Contributors -- Index.
摘要:"Parkinson's disease is the second most common neurodegenerative disorder in the world after Alzheimer's disease. Thanks to the pioneering works of Arvid Carlson in the 20th century identifying dopamine as the main neurochemical agent involved in Parkinson's disease's onset and progress, our understanding of the neuropathology has increased. The elaboration of L-Dopa as the first pharmacological treatment approach has brought new hope for curing or at least slowing the neurodegenerative progress and the decline of motor and cognitive functions in Parkinson's disease patients. To date, imaging techniques along with genetic and biochemical tools have allowed scientists and clinicians to predict and diagnose the disease several years prior to the motor disorder's appearance. Experimental and Clinical Evidence of the Neuropathology of Parkinson's Disease sheds light on the history of Parkinson's disease as well as the recent literature on theepidemiological data worldwide including the prevalence of the disease, the morbimortality rates, and the sex dimorphism and aging components. It addresses the current neuropathological evidence of Parkinson's disease, including the latestdiscoveries in terms of neuropathology and treatments available or under clinical trials with the efficacy and limitations of each. Covering topics such as epidemiology, stem cells, and neuropathology, this premier reference source is an excellent resource for clinicians, physicians, epidemiologists, neuroscientists, microbiologists, biochemists, pharmacologists, toxicologists, medical professionals, nurses, medical students and educators, librarians, researchers, and academicians."--
